Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study

医学 西罗莫司 不利影响 回顾性队列研究 治疗药物监测 入射(几何) 内科学 外科 药代动力学 物理 光学
作者
Ya‐Hui Hu,Yuetao Zhao,Hong‐Li Guo,Yue Li,Yuanyuan Zhang,Sheng Wang,Xuan‐Sheng Ding,Jijun Zou,Feng Chen
出处
期刊:Pharmaceuticals [MDPI AG]
卷期号:17 (10): 1255-1255
标识
DOI:10.3390/ph17101255
摘要

Objectives: Sirolimus (SRL), a mammalian target of rapamycin inhibitor, has been widely used to treat patients with vascular anomalies (VAs). The objectives of this study were to summarize the routine blood SRL monitoring data for VAs children, to investigate the factors contributing to the variable blood SRL concentrations and to evaluate the efficacy and safety of SRL therapy. Methods: VAs patients with routine blood SRL monitoring from July 2017 to April 2022 at the Department of Burns and Plastic Surgery, Children’s Hospital of Nanjing Medical University were retrospectively collected. Clinical data were obtained from the hospital information system. Results: In total, 67 children (35 females) were enrolled. The therapeutic drug monitoring data showed that the range of measured blood trough concentrations (Ctrough) was 3.6–46.8 ng/mL. At the initial measurements, only 33% of patients were in the target concentration range (10–15 ng/mL). But this proportion became 54% at the last measurements. The whole blood-Ctrough-to-daily dose (Ctrough/Dose) ratio was significantly associated with age and body weight (BW). The patients’ laboratory results did not change significantly after SRL treatment. Although the incidence of adverse events was relatively high (44.8%), most of them were mild and tolerable. 70.3% patients had total responses to SRL, whereas 29.7% children exhibited stable disease or progressive disease. No significant differences were found in Ctrough between the total response group and non-response group. Conclusions: This retrospective study revealed a high variability in SRL blood concentrations in Chinese children with VAs. Of note, pediatric patients with older age and a higher BW had a lower Ctrough/Dose ratio. It is a concern whether the range of 10–15 ng/mL is feasible for Chinese children based only on our study. Further studies recruiting more patients are required to redefine the target reference range for children with VAs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
qnd完成签到,获得积分10
2秒前
科研混子完成签到,获得积分10
2秒前
007完成签到 ,获得积分10
4秒前
Thi发布了新的文献求助10
4秒前
CodeCraft应助随波逐流采纳,获得10
5秒前
健康的绮晴完成签到,获得积分10
5秒前
dd完成签到,获得积分10
5秒前
无花果应助anananand采纳,获得10
5秒前
007关注了科研通微信公众号
7秒前
A9W01U完成签到,获得积分10
10秒前
blawxx完成签到,获得积分10
10秒前
Jasper应助Muggle采纳,获得10
12秒前
12秒前
宁宁壹号完成签到,获得积分10
14秒前
快乐的香菇关注了科研通微信公众号
15秒前
星辰大海应助Thi采纳,获得10
17秒前
18秒前
lhb发布了新的文献求助10
18秒前
叶子发布了新的文献求助10
21秒前
SciGPT应助科研通管家采纳,获得10
23秒前
烟花应助科研通管家采纳,获得10
23秒前
星辰大海应助科研通管家采纳,获得10
23秒前
李爱国应助科研通管家采纳,获得10
23秒前
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
timemaster666应助科研通管家采纳,获得50
23秒前
InfoNinja应助科研通管家采纳,获得30
23秒前
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
25秒前
金角大王发布了新的文献求助10
25秒前
27秒前
30秒前
筱灬发布了新的文献求助10
30秒前
30秒前
金角大王完成签到,获得积分10
31秒前
35秒前
35秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3155790
求助须知:如何正确求助?哪些是违规求助? 2807042
关于积分的说明 7871703
捐赠科研通 2465404
什么是DOI,文献DOI怎么找? 1312221
科研通“疑难数据库(出版商)”最低求助积分说明 629958
版权声明 601905